Study Enrollment

Your details will not be published or shared.

Clinical Trial

(HLA-G) To Develop and Optimize Innovative Methods and Therapies that Prevent Rejection and Prolong Transplant Survival in Patients

Subjects who have had a kidney transplant rejection are being asked to allow site to collect two to four blood draws of plasma (4 teaspoons/20 ml). A protein called human leukocyte antigen (HLA) has been identified on the surface of white blood cells that might be associated with longer kidney transplant survival. The HLA proteins are called monomers and Dimers. The purpose of our study is to identify which form of HLA-G (monomer vs. dimer) is associated with longer kidney transplant survival. NOTE: Please be made aware that at this time the Title of this project is being changed from ?Monomer and dimer forms of soluble HLA-G and their inhibitory receptors in Kidney Graft Acceptance? to that which is in Short Title

Eligibility Criteria

  • 1. Subject is between 13 and 70 years of age 2. Subject has to have a living kidney transplant or cadaver kidney transpant 3. Subject must have the ability to sign written informed consent 4. Control group will include subject that have never received an organ transpant or currently pregnant or on any immunosuppressive therapy. 5. Must have had a kidney transplant rejection

Contact Information

    Laura Mulloy, DO

    706 721 2861